Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Comment by indaknownewfieon Sep 22, 2018 6:42am
211 Views
Post# 28669688

RE:Expect European Pharma partner with Ph. 3 clinical data

RE:Expect European Pharma partner with Ph. 3 clinical dataI agree with everything you are saying Leaf and do not understand why we are not at $2 a share now, I;m long on TBP but Kalytera Therapeutics is about to commence phase 3 too with two different patents involving CBD for treatment of GVHD after organ transplant. They likwise have a CBD/ naproxen subjugate combo in the mix that has advanced too which will be marketed for pain relief in response to opioids. 
<< Previous
Bullboard Posts
Next >>